Sino Medical Sciences Technology Inc. (SHA:688108)
China
· Delayed Price · Currency is CNY 9.49
+0.02 (0.21%)
Apr 24, 2025, 2:45 PM CST
SHA:688108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Operating Revenue | 458.74 | 340.02 | 192.58 | 194.1 | 326.25 | Upgrade
|
| Other Revenue | - | 3.23 | 0.27 | 0.26 | 1.17 | Upgrade
|
| Revenue | 458.74 | 343.26 | 192.85 | 194.36 | 327.42 | Upgrade
|
| Revenue Growth (YoY) | 33.64% | 77.99% | -0.77% | -40.64% | -24.89% | Upgrade
|
| Cost of Revenue | - | 145.64 | 85.64 | 60.25 | 67.1 | Upgrade
|
| Gross Profit | 458.74 | 197.62 | 107.21 | 134.11 | 260.32 | Upgrade
|
| Selling, General & Admin | - | 157.77 | 174.76 | 150.02 | 138.04 | Upgrade
|
| Research & Development | - | 114.1 | 152.8 | 148.93 | 108.73 | Upgrade
|
| Other Operating Expenses | 475.69 | 2.15 | 0.77 | 1.8 | 1.16 | Upgrade
|
| Operating Expenses | 475.69 | 272.61 | 329.66 | 300.21 | 248.42 | Upgrade
|
| Operating Income | -16.95 | -74.99 | -222.45 | -166.1 | 11.9 | Upgrade
|
| Interest Expense | - | -3.75 | -2.55 | -2.2 | - | Upgrade
|
| Interest & Investment Income | - | 2.63 | 2.98 | 4.68 | 12.98 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.01 | 0.52 | -0.57 | -0.78 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.18 | -0.18 | -0.17 | -0.16 | 4.58 | Upgrade
|
| EBT Excluding Unusual Items | -17.14 | -77.3 | -221.67 | -164.36 | 28.68 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -4.67 | -4.11 | -0.29 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -1.55 | -2.21 | 0.11 | 0.01 | Upgrade
|
| Asset Writedown | - | - | - | - | -0.02 | Upgrade
|
| Other Unusual Items | - | 15.66 | 6.65 | 1.43 | 0.18 | Upgrade
|
| Pretax Income | -17.14 | -67.86 | -221.34 | -163.1 | 28.84 | Upgrade
|
| Income Tax Expense | -18.66 | -24.46 | -48.03 | -31.8 | 6.35 | Upgrade
|
| Earnings From Continuing Operations | 1.52 | -43.4 | -173.31 | -131.3 | 22.49 | Upgrade
|
| Minority Interest in Earnings | - | 3.77 | 10.93 | 0.53 | - | Upgrade
|
| Net Income | 1.52 | -39.63 | -162.38 | -130.77 | 22.49 | Upgrade
|
| Net Income to Common | 1.52 | -39.63 | -162.38 | -130.77 | 22.49 | Upgrade
|
| Net Income Growth | - | - | - | - | -75.02% | Upgrade
|
| Shares Outstanding (Basic) | 380 | 396 | 406 | 409 | 410 | Upgrade
|
| Shares Outstanding (Diluted) | 380 | 396 | 406 | 409 | 410 | Upgrade
|
| Shares Change (YoY) | -4.04% | -2.38% | -0.66% | -0.33% | 9.29% | Upgrade
|
| EPS (Basic) | 0.00 | -0.10 | -0.40 | -0.32 | 0.05 | Upgrade
|
| EPS (Diluted) | 0.00 | -0.10 | -0.40 | -0.32 | 0.05 | Upgrade
|
| EPS Growth | - | - | - | - | -79.17% | Upgrade
|
| Free Cash Flow | - | -10.83 | -222.07 | -218.58 | -42.27 | Upgrade
|
| Free Cash Flow Per Share | - | -0.03 | -0.55 | -0.54 | -0.10 | Upgrade
|
| Gross Margin | 100.00% | 57.57% | 55.59% | 69.00% | 79.51% | Upgrade
|
| Operating Margin | -3.70% | -21.84% | -115.35% | -85.46% | 3.64% | Upgrade
|
| Profit Margin | 0.33% | -11.54% | -84.20% | -67.28% | 6.87% | Upgrade
|
| Free Cash Flow Margin | - | -3.16% | -115.15% | -112.46% | -12.91% | Upgrade
|
| EBITDA | 31.95 | -26.09 | -172.09 | -113.86 | 50.21 | Upgrade
|
| EBITDA Margin | 6.96% | -7.60% | -89.23% | -58.58% | 15.33% | Upgrade
|
| D&A For EBITDA | 48.9 | 48.9 | 50.36 | 52.24 | 38.3 | Upgrade
|
| EBIT | -16.95 | -74.99 | -222.45 | -166.1 | 11.9 | Upgrade
|
| EBIT Margin | -3.70% | -21.84% | -115.35% | -85.46% | 3.64% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 22.01% | Upgrade
|
| Revenue as Reported | - | 343.26 | 192.85 | 194.36 | 327.42 | Upgrade
|
| Advertising Expenses | - | 1.13 | 2.45 | - | 10.21 | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.